Advertisement
Canada markets closed
  • S&P/TSX

    21,788.48
    -60.11 (-0.28%)
     
  • S&P 500

    5,469.30
    +21.43 (+0.39%)
     
  • DOW

    39,112.16
    -299.05 (-0.76%)
     
  • CAD/USD

    0.7326
    +0.0003 (+0.04%)
     
  • CRUDE OIL

    80.87
    +0.04 (+0.05%)
     
  • Bitcoin CAD

    84,638.76
    +2,332.41 (+2.83%)
     
  • CMC Crypto 200

    1,283.48
    +34.35 (+2.75%)
     
  • GOLD FUTURES

    2,332.40
    +1.60 (+0.07%)
     
  • RUSSELL 2000

    2,022.35
    -8.47 (-0.42%)
     
  • 10-Yr Bond

    4.2380
    -0.0100 (-0.24%)
     
  • NASDAQ futures

    19,996.00
    +23.75 (+0.12%)
     
  • VOLATILITY

    12.84
    -0.49 (-3.68%)
     
  • FTSE

    8,247.79
    -33.76 (-0.41%)
     
  • NIKKEI 225

    39,397.86
    +224.71 (+0.57%)
     
  • CAD/EUR

    0.6833
    +0.0001 (+0.01%)
     

Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference

LEXINGTON, Mass., May 23, 2024--(BUSINESS WIRE)--Agenus Inc. ("Agenus") (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, and Robin Taylor, Chief Commercial Officer, will participate in a fireside chat and investor one-on-ones at the upcoming Goldman Sachs Global Healthcare Conference on June 10th – 13th in Miami Beach, Florida. The fireside chat will take place at 8:00 a.m. ET on June 12th.

A live webcast and replay of the fireside chat will be accessible on the company’s website at https://investor.agenusbio.com/events-and-presentations/.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240523361904/en/

Contacts

Investor
917-362-1370
investor@agenusbio.com

Media
612-839-6748
communications@agenusbio.com